1 |
Khuri FR, Nemunaitis J, Ganly I, Arsenau J, Tannock IF, Romel L, et al. A controlled trial of intratumoral ONYX-015, a selectively-replicating adenovirus, in combination with cisplatin and 5-fluorouracil in patients with recurrent head and neck cancer. Nat Med 2000;6:879:885.
DOI
ScienceOn
|
2 |
D'Souza G, Kreimer AR, Viscidi R, Pawlita M, Fakhry C, Koch WM, et al. Casecontrol study of human papillomavirus and oropharyngeal cancer. New Engl J Med 2007;356:1944-56.
DOI
ScienceOn
|
3 |
Sisk EA, Soltys SG, Zhu S, Fisher SG, Carey TE, Bradford CR. Human papillomavirus and p53 mutational status as prognostic factors in head and neck carcinoma. Head Neck 2002;24:841.9.
DOI
ScienceOn
|
4 |
Bonner JA, Harari PM, Giralt J, et al. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med 2006;354:567-78.
DOI
ScienceOn
|
5 |
Glazer CA, Chang SS, Ha PK, Califano JA. Applying the molecular biology and epigenetics of head and neck cancer in everyday clinical practice.Oral Oncol. 2009;45:440-6.
DOI
ScienceOn
|
6 |
McDonald JS, Jones H, Pavelic ZP, Stambrook PJ, Gluckman JL. Immunhistochemical detection of the H-ras, K-ras, and N-ras oncogenes in squamous cell carcinoma of the head and neck. J Oral Pathol Med 1994;23:342-346.
DOI
ScienceOn
|
7 |
Kyomoto R, Kumazawa H, Toda Y, Sakaida N, Okamura A, Iwanaga M, et al. Cyclin D1 gene amplification is a more potent prognostic factor than its protein overexpression in human head and neck squamous cell carcinoma. Int J Cancer 1997;74:576-81.
DOI
ScienceOn
|
8 |
Esteller M, Silva JM, Dominguez G, Bonilla F, Matias- Guiu X, Lerma E, Bussaglia E, Prat J, Harkes IC, Repasky EA, Gabrielson E, Schutte M, Baylin SB, Herman JG.Promoter hypermethylation and BRCA1 inactivation in sporadic breast and ovarian tumors. J Natl Cancer Inst. 2000;5;92:564-9.
DOI
ScienceOn
|
9 |
Williams HK. Molecular pathogenesis of oral squamous carcinoma. J Clin Pathol: Mol Pathol 2000;53:165-172.
DOI
ScienceOn
|
10 |
Pai SI, Westra WH. Molecular pathology of head and neck cancer: implications for diagnosis, prognosis, and treatment.Annu Rev Pathol. 2009;4:49-70. Review.
DOI
ScienceOn
|
11 |
Dobosy JR, Selker EU. Emerging connections between DNA methylation and histone acetylation. Cell Mol Life Sci 2001;58:721-7.
DOI
ScienceOn
|
12 |
Chang X, Monitto CL, Demokan S, Kim MS, Chang SS, Zhong X, Califano JA, Sidransky D. dentification of hypermethylated genes associated with cisplatin resistance in human cancers. Cancer Res. 2010;1;70:2870-9.
DOI
|
13 |
Cripps C, Winquist E, Devries MC, Stys-Norman D, Gilbert R. Epidermal growth factor receptor targeted therapy in stages III and IV head and neck cancer.Curr Oncol. 2010;17:37-48.
|
14 |
Ishitoya J, Toriyama M, Oguchi N, Kitamura K, Ohshima M, Asano K, et al. Gene amplification and overexpression of EGF receptor in squamous cell carcinomas of the head and neck. Brit J Cancer 1989;59:559.62.
DOI
ScienceOn
|
15 |
Bockmuhl U, Wolf G, Schmidt S, Schwendel A, Jahnke V, Dietel M, et al. Genomic alterations associated with malignancy in head and neck cancer. Head Neck 1998;20:145-151.
DOI
ScienceOn
|
16 |
Nagpal JK, Das BR. Oral cancer: reviewing the present understanding of its molecular mechanism and exploring the future directions for its effective management. Oral Oncol. 2003;39:213-21. Review.
DOI
ScienceOn
|
17 |
Rosin MP, Cheng X, Poh C, Lam WL, Huang Y, Lovas J, et al. Use of allelic loss to predict malignant risk for low-grade oral epithelial dysplasia. Clin Cancer Res 2000;6:357-6
|
18 |
Nobori T, Miura K, Wu DJ, Lois A, Takabayashi K, Carson DA. Deletions of the cyclin-dependent kinase-4 inhibitor gene in multiple human cancers. Nature. 1994;368:753-6.
DOI
ScienceOn
|
19 |
Partridge M, Emilion G, Pateromichelakis S, A'Hern R, Lee G, Phillips E, et al. The prognostic significance of allelic imbalance at key chromosomal loci in oral cancer. Br J Cancer 1999;79:1821-1827.
DOI
ScienceOn
|
20 |
Copper MP, Jovanovic A, Nauta JJP, Braakhuis BJM, de Vries N, van der Waal I, et al. Role of genetic factors in the etiology of squamous cell carcinoma of the head and neck. Arch Otolaryngol Head Neck Surg 1995;121:157-60
DOI
ScienceOn
|
21 |
Foulkes WD, Brunet J-S, Sieh W, Black MJ, Shenouda G, Narod SA. Familial risks of squamous cell carcinoma of thehead and neck: a retrospective case-control study. Br Med J 1996;313:716.20.
DOI
ScienceOn
|
22 |
Sanchez-Cespedes M, Esteller M, Wu L, Nawroz-Danish H, Yoo GH, Koch WM, Jen J, Herman JG, Sidransky D.Gene promoter hypermethylation in tumors and serum of head and neck cancer patients. Cancer Res. 2000;15;892-5.
|
23 |
Williams ME, Gaffey MJ, Weiss LM, et al. Chromosome 11Q13 amplification in head and neck squamous cell carcinoma. Arch Otolaryngol Head Neck Surg 1993;119:1238-43.
DOI
ScienceOn
|
24 |
Califano J, van der Riet P, Westra W, Nawroz H, Clayman G, Piantadosi S, Corio R, Lee D, Greenberg B, Koch W, Sidransky D. Genetic Progression Model for Head and Neck Cancer: Implications for Field Cancerization. Cancer Res. 1996;56:2488-92.
|
25 |
Bockmuhl U, Schwendel A, Dietel M, Petersen I. Distinct patterns of chromosomal alterations in highand low-grade head and neck squamous cell carcinomas. Cancer Res 1996;56:5325-9.
|
26 |
Callender T, el-Naggar AK, Lee MS, et al. PRAD-1 (CCND1)/cyclin D1 oncogene amplification in primary head and neck squamous cell carcinoma. Cancer 1994;74:152-8.
DOI
ScienceOn
|
27 |
Bockmuhl U, Kuchler I, Petersen I. Improved prognostic assessment of head-neck carcinomas by new genetic markers. Hno 2000;48:451-6
DOI
ScienceOn
|
28 |
Scully C, Field JK, Tanzawa H. Genetic aberrations in oral or head and neck squamous cell carcinoma 2: chromosomal aberrations. Oral Oncol 2000;36:311.327.
|
29 |
Parkin DM, Laara E, Muir CS. Estimates of the worldwide frequency of sixteen major cancers in 1980. Int J Cancer 1988;41:184-9
DOI
|
30 |
Figueiredo ML, Kim Y, Zhou XC, Myers JN, Wong DT. Molecular mechanisms of head and neck cancer. Drug Discov Today 2004:1:273-281
DOI
ScienceOn
|
31 |
Shin DM, Lee JS, Lippman SM, Lee JJ, Tu ZN, Choi G, et al. p53 expressions: predicting recurrence and second primary tumors in head and neck squamous cell carcinoma. J Natl Cancer Inst 1996;88:519-29.
DOI
ScienceOn
|
32 |
Slaughter DP, Southwick HW, Smejkal W. Field cancerization in oral stratified squamous epithelium; clinical implications of multicentric origin. Cancer 1953;6:963-8.I
DOI
ScienceOn
|
33 |
Mellin H, Friesland S, Lewensohn R, Dalianis T, Munck-Wikland E. Humanpapillomavirus (HPV) DNA in tonsillar cancer: clinical correlates, risk of relapse, and survival. Int J Cancer 2000;89:300.4.
DOI
ScienceOn
|
34 |
Strome SE, Savva A, Brissett AE, Gostout BS, Lewis J, Clayton AC, et al. Squamous cell carcinoma of the tonsils: a molecular analysis of HPV associations. Clin Cancer Res 2002;8:1093-100.
|
35 |
Gillespie MB, Rubinchik S, Hoel B, Sutkowski N.Curr Treat Options Oncol. Human papillomavirus and oropharyngeal cancer: what you need to know in 2009. 2009;10:296-307.
DOI
ScienceOn
|
36 |
Folkman J. Tumor angiogenesis: therapeutic implications. N Engl J Med. 1971;18;285:1182-6.
DOI
ScienceOn
|
37 |
Patel V, Leethanakul C, Gutkind JS. New approaches to the understanding of the molecular basis of oral cancer. Crit Rev Oral Biol Med 2001;12:55.63.
DOI
ScienceOn
|
38 |
Brennan JA, Mao L, Hruban RH, et al. Molecular assessment of histopathological staging in squamouscell carcinoma of the head and neck. N Engl J Med 1995;332:429-35.
DOI
ScienceOn
|
39 |
Liggett Jr WH, Sidransky D. Role of the p16 tumor suppressor gene in cancer. J Clin Oncol 1998;16:1197-206.
DOI
|
40 |
Bettendorf O, Piffko J, Bankfalvia A. Prognostic and predictive factors in oral squamous cell cancer: important tools for planning individual therapy? Oral Oncology 2004;40:110-119
DOI
ScienceOn
|
41 |
National Cancer Institute, Study Estimates Overall HPV Prevalence in U.S. Women http://www.cancer.gov/cancertopics/causes/hpv/hpv-prevalence0308
|
42 |
Mehanna H, Jones TM, Gregoire V, Ang KK. Oropharyngeal carcinoma related to human papillomavirus.BMJ. 2010;25;340:c1439.
DOI
|
43 |
Werness BA, Levine AJ, Howley PM. Association of human papillomavirus types 16 and 18 E6 proteins with p53. Science 1990;248:76-9.
DOI
|
44 |
Cruz IB, Snijders PJ, Steenbergen RD, Meijer CJ, Snow GB, Walboomers JM, et al. Age-dependence of human papillomavirus DNA presence in oral squamous cell carcinomas. Eur J Cancer B Oral Oncol 1996;32:55.62.
DOI
ScienceOn
|
45 |
Xie X, Clausen OP, De Angelis P, Boysen M. The prognostic value of spontaneous apoptosis. Bax, Bcl-2, and p53 in oral squamous cell carcinoma of the tongue. Cancer 1999;86:913-20
DOI
ScienceOn
|
46 |
Xu J, Gimenez-Conti IB, Cunningham JE, et al. Alterations of p53, cyclin D1, Rb, and H-ras in human oral carcinomas related to tobacco use. Cancer 1998;83:204-12.
DOI
ScienceOn
|
47 |
Serrano M, Hannon GJ, Beach D. A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4. Nature 1993;366:704-707.
DOI
ScienceOn
|
48 |
Gleich LL, Salamone FN. Molecular genetics of head and neck cancer. Cancer Control 2002;9:369-378.
DOI
|
49 |
Nigro JM, Baker SJ, Preisinger AC, et al. Mutations in the p53 gene occur in diverse human tumour types. Nature 1989;342:705-8.
DOI
ScienceOn
|
50 |
Field JK, Pavelic ZP, Spandidos DA, et al. The role of the p53 tumor suppressor gene in squamous cell carcinoma of the head and neck. Arch Otolaryngol Head Neck Surg 1993;119:1118-22.
DOI
ScienceOn
|
51 |
Le Tourneau C, Faivre S, Siu LL. Molecular targeted therapy of head and neck cancer: review and clinical development challenges. Eur J Cancer. 2007;43:2457-66.
DOI
ScienceOn
|
52 |
Herman JG, Baylin SB. Gene silencing in cancer in association with promoter hypermethylation. New Engl J Med 2003;349:2042.54.
DOI
ScienceOn
|
53 |
Rubin Grandis J, Melhem MF, Gooding WE, Day R, Holst VA, Wagener MM, et al. Levels of TGF-alpha and EGFR protein in head and neck squamous cell carcinoma and patient survival. J Natl Cancer Inst 1998;90:824.32.
DOI
ScienceOn
|
54 |
Bentzen SM, Atasoy BM, Daley FM, Dische S, Richman PI, Saunders MI, et al. Epidermal growth factor receptor expression in pretreatment biopsies from head and neck squamous cell carcinoma as a predictive factor for a benefit from accelerated radiation therapy in a randomized controlled trial. J Clin Oncol 2005;23:5560.7.
DOI
ScienceOn
|